Figure 2From: Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomasProgression-free survival rates of the HFRT group. Three-year and 5-year PFS rates were 64.4% and 53.7%, respectively.Back to article page